DeepMed Research

Peking University Peoples Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Patient-reported Outcomes of Postsurgical Pain and Health Related Quality of Life

Completed

Conditions: Post Surgical Pain

First Posted Date: 2019-04-25

Last Posted Date: 2024-06-05

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 2000

Registration Number: NCT03926858

Locations: 🇨🇳
Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China
🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳
The Third People's Hospital of Hubei Province, Wuhan, Hubei, China

and more 20 locations

Impact of Intensive Follow-up for Bone Metastasis on Characteristics and Prognosis of Chinese Breast Cancer Patients

Completed

Conditions: Breast Cancer
Bone Metastases

Interventions: Diagnostic Test: Intensive screening / routine screening

First Posted Date: 2019-04-23

Last Posted Date: 2019-04-23

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 1500

Registration Number: NCT03924609

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

Changes of Pelvic Floor Functions in Women at Different Postpartum Time

Conditions: Pelvic Floor Disorders

First Posted Date: 2019-04-19

Last Posted Date: 2019-04-19

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 130

Registration Number: NCT03921463

Locations: 🇨🇳
The Peking University People's Hospital, Beijing, Beijing, China

Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab

Conditions: Biomarkers for Efficacy and Toxicity
Drug Resistance to Famitinib and Camrelizumab

First Posted Date: 2019-04-18

Last Posted Date: 2020-02-06

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 40

Registration Number: NCT03919539

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

Combination of Danazole With Berberine in the Treatment of ITP

Phase 2

Conditions: Corticosteroid-resistant or Relapsed ITP

Interventions: Drug: Berberine plus danazol

First Posted Date: 2019-04-10

Last Posted Date: 2020-09-25

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 55

Registration Number: NCT03909763

Locations: 🇨🇳
Peking University Institute of Hematology, Beijing, Beijing, China

Transcatheter Intra-arterial Limb Infusion of Cisplatin for Extremity Osteosarcoma

Not Applicable

Completed

Conditions: Overall Survival
Pathological Response
Event-free Survival
Local-recurrence Free Survival

Interventions: Drug: Cisplatin

First Posted Date: 2019-04-10

Last Posted Date: 2021-01-05

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 99

Registration Number: NCT03909776

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

Anlotinib Hydrochloride Combined With Liposomal Doxorubicin in the Treatment of Locally Advanced or Metastatic Soft Tissue Sarcoma

Phase 2

Conditions: Sarcoma

Interventions: Drug: Anlotinib+ Liposomal Doxorubicin

First Posted Date: 2019-03-19

Last Posted Date: 2019-03-21

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 48

Registration Number: NCT03880695

Locations: 🇨🇳
First Hospital of Jilin University, Chang chun, Jilin, China
🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China

and more 5 locations

Impact of CYP3A4*1G Polymorphism on Non-analgesic Effects of Fentanyl in Chinese Han Patients

Conditions: Fentanyl

First Posted Date: 2019-03-11

Last Posted Date: 2019-09-06

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 200

Registration Number: NCT03869346

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

Fluorescent Thoracoscopy Used in Surgery for Palmar Hyperhidrosis

Completed

Conditions: Palmar Hyperhidrosis

Interventions: Procedure: Near-Infrared Imaging Thoracoscopy

First Posted Date: 2019-02-15

Last Posted Date: 2019-02-15

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 89

Registration Number: NCT03840655

Locations: 🇨🇳
Peking University People'S Hospital, Beijing, Beijing, China

Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA

Not Applicable

Conditions: Engraft Failure
Aplastic Anemia
Stem Cell Transplant Complications

Interventions: Drug: Fludarabine

First Posted Date: 2019-01-30

Last Posted Date: 2020-03-10

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 55

Registration Number: NCT03821987

Locations: 🇨🇳
Peking University Institute of Hematology,People's hospital Peking University, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy